Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 16Terminated 12Recruiting 7Unknown 4Withdrawn 3Active not recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 48Lymphoid 11Other hematologic neoplasm 7Thoracic 3Genitourinary 3CNS 3Sarcoma 1Other 1Myeloid 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 2Lung Neoplasms 2Vomiting 1Small Cell Lung Carcinoma 1Nausea 1

Interventions

Carboplatin 40Cisplatin 37Pemetrexed 33Radiotherapy 23Paclitaxel 22pembrolizumab 20durvalumab 19Docetaxel 19Gemcitabine 18Nivolumab 15Radiosurgery 14Etoposide 13atezolizumab 11Erlotinib Hydrochloride 11Taxes 8Magnetic Resonance Spectroscopy 8Drug Therapy 8Bevacizumab 8Cyclophosphamide 7Platinum 6Gefitinib 6Surveys and Questionnaires 5Biopsy 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5sotorasib 4Ramucirumab 4Radiation 4Immunotherapy 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Dexamethasone × Thoracic × Clear all
NCT04267913 2020-11-20

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

NCT03334487 2018-12-26

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

AbbVie

Phase 3 Withdrawn
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT00891761 2015-04-17

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

GlaxoSmithKline

Phase 3 Withdrawn
Thoracic

Lung Neoplasms, Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡